Literature DB >> 28138159

Caspase-3-dependent cleavage of Akt modulates tau phosphorylation via GSK3β kinase: implications for Alzheimer's disease.

J Chu1, E Lauretti1, D Praticò1.   

Abstract

The pathological hallmark of Alzheimer's disease (AD) is accumulation of misfolded amyloid-β peptides and hyperphosphorylated tau protein in the brain. Increasing evidence suggests that serine-aspartyl proteases-caspases are activated in the AD brain. Previous studies identified a caspase-3 cleavage site within the amyloid-β precursor protein, and a caspase-3 cleavage of tau as the mechanisms involved in the development of Aβ and tau neuropathology, respectively. However, the potential role that caspase-3 could have on tau metabolism remains unknown. In the current studies, we provide experimental evidence that caspase-3 directly and specifically regulates tau phosphorylation, and demonstrate that this effect is mediated by the GSK3β kinase pathway via a caspase-3-dependent cleavage of the protein kinase B (also known as Akt). In addition, we confirm these results in vivo by using a transgenic mouse model of AD. Collectively, our findings demonstrate a new role for caspase-3 in the neurobiology of tau, and suggest that therapeutic strategies aimed at inhibiting this protease-dependent cleavage of Akt may prove beneficial in preventing tau hyperphosphorylation and subsequent neuropathology in AD and related tauopathies.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28138159     DOI: 10.1038/mp.2016.214

Source DB:  PubMed          Journal:  Mol Psychiatry        ISSN: 1359-4184            Impact factor:   15.992


  43 in total

1.  Direct regulation of the Akt proto-oncogene product by phosphatidylinositol-3,4-bisphosphate.

Authors:  T F Franke; D R Kaplan; L C Cantley; A Toker
Journal:  Science       Date:  1997-01-31       Impact factor: 47.728

2.  Caspase 3 activity is required for skeletal muscle differentiation.

Authors:  Pasan Fernando; John F Kelly; Kim Balazsi; Ruth S Slack; Lynn A Megeney
Journal:  Proc Natl Acad Sci U S A       Date:  2002-08-12       Impact factor: 11.205

3.  Accumulation of caspase cleaved amyloid precursor protein represents an early neurodegenerative event in aging and in Alzheimer's disease.

Authors:  Ming Zhao; Joseph Su; Elizabeth Head; Carl W Cotman
Journal:  Neurobiol Dis       Date:  2003-12       Impact factor: 5.996

4.  Erythroid expansion and survival in response to acute anemia stress: the role of EPO receptor, GATA-1, Bcl-xL and caspase-3.

Authors:  Gualberto Rodrigo Aispuru; María Victoria Aguirre; José Andrés Aquino-Esperanza; Carolina Noelia Lettieri; Julián Antonio Juaristi; Nora Cristina Brandan
Journal:  Cell Biol Int       Date:  2008-04-10       Impact factor: 3.612

5.  Involvement of caspases in proteolytic cleavage of Alzheimer's amyloid-beta precursor protein and amyloidogenic A beta peptide formation.

Authors:  F G Gervais; D Xu; G S Robertson; J P Vaillancourt; Y Zhu; J Huang; A LeBlanc; D Smith; M Rigby; M S Shearman; E E Clarke; H Zheng; L H Van Der Ploeg; S C Ruffolo; N A Thornberry; S Xanthoudakis; R J Zamboni; S Roy; D W Nicholson
Journal:  Cell       Date:  1999-04-30       Impact factor: 41.582

6.  Caspase-cleaved tau exhibits rapid memory impairment associated with tau oligomers in a transgenic mouse model.

Authors:  YoungDoo Kim; Hyunwoo Choi; WonJae Lee; Hyejin Park; Tae-In Kam; Se-Hoon Hong; Jihoon Nah; Sunmin Jung; Bora Shin; Huikyong Lee; Tae-Yong Choi; Hyosun Choo; Kyung-Keun Kim; Se-Young Choi; Rakez Kayed; Yong-Keun Jung
Journal:  Neurobiol Dis       Date:  2015-12-17       Impact factor: 5.996

7.  Caspase-3 in the central nervous system: beyond apoptosis.

Authors:  Marcello D'Amelio; Morgan Sheng; Francesco Cecconi
Journal:  Trends Neurosci       Date:  2012-07-14       Impact factor: 13.837

8.  Caspase activation is required for terminal erythroid differentiation.

Authors:  Y Zermati; C Garrido; S Amsellem; S Fishelson; D Bouscary; F Valensi; B Varet; E Solary; O Hermine
Journal:  J Exp Med       Date:  2001-01-15       Impact factor: 14.307

9.  Stimulation of EphB2 attenuates tau phosphorylation through PI3K/Akt-mediated inactivation of glycogen synthase kinase-3β.

Authors:  Jun Jiang; Zhi-Hao Wang; Min Qu; Di Gao; Xiu-Ping Liu; Ling-Qiang Zhu; Jian-Zhi Wang
Journal:  Sci Rep       Date:  2015-06-29       Impact factor: 4.379

10.  Inhibition of Gsk3β activity improves β-cell function in c-KitWv/+ male mice.

Authors:  Zhi-Chao Feng; Lisa Donnelly; Jinming Li; Mansa Krishnamurthy; Matthew Riopel; Rennian Wang
Journal:  Lab Invest       Date:  2012-01-16       Impact factor: 5.662

View more
  32 in total

Review 1.  The cholinergic system in the pathophysiology and treatment of Alzheimer's disease.

Authors:  Harald Hampel; M-Marsel Mesulam; A Claudio Cuello; Martin R Farlow; Ezio Giacobini; George T Grossberg; Ara S Khachaturian; Andrea Vergallo; Enrica Cavedo; Peter J Snyder; Zaven S Khachaturian
Journal:  Brain       Date:  2018-07-01       Impact factor: 13.501

2.  Rho-kinase ROCK inhibitors reduce oligomeric tau protein.

Authors:  Tadanori Hamano; Norimichi Shirafuji; Shu-Hui Yen; Hirotaka Yoshida; Nicholas M Kanaan; Kouji Hayashi; Masamichi Ikawa; Osamu Yamamura; Youshi Fujita; Masaru Kuriyama; Yasunari Nakamoto
Journal:  Neurobiol Aging       Date:  2019-12-16       Impact factor: 4.673

3.  Enriched physical environment reverses spatial cognitive impairment of socially isolated APPswe/PS1dE9 transgenic mice before amyloidosis onset.

Authors:  Min Cao; Pan-Pan Hu; Yan-Li Zhang; Yi-Xin Yan; Christopher B Shields; Yi-Ping Zhang; Gang Hu; Ming Xiao
Journal:  CNS Neurosci Ther       Date:  2017-12-23       Impact factor: 5.243

Review 4.  Beneficial Effects of Fingolimod in Alzheimer's Disease: Molecular Mechanisms and Therapeutic Potential.

Authors:  Efthalia Angelopoulou; Christina Piperi
Journal:  Neuromolecular Med       Date:  2019-07-16       Impact factor: 3.843

5.  Sarcococca saligna ameliorated D-galactose induced neurodegeneration through repression of neurodegenerative and oxidative stress biomarkers.

Authors:  Uzma Saleem; Zunera Chauhdary; Sumera Islam; Aimen Zafar; Rana O Khayat; Norah A Althobaiti; Ghulam Mujtaba Shah; Mohammed Alqarni; Muhammad Ajmal Shah
Journal:  Metab Brain Dis       Date:  2022-07-26       Impact factor: 3.655

Review 6.  Tau Toxicity in Neurodegeneration.

Authors:  Shu-Yu Liang; Zuo-Teng Wang; Lan Tan; Jin-Tai Yu
Journal:  Mol Neurobiol       Date:  2022-03-31       Impact factor: 5.682

7.  Lactoferrin modification of berberine nanoliposomes enhances the neuroprotective effects in a mouse model of Alzheimer's disease.

Authors:  Lin Wang; Bi-Qiang Zhou; Ying-Hong Li; Qian-Qian Jiang; Wei-Hong Cong; Ke-Ji Chen; Xiao-Min Wen; Zheng-Zhi Wu
Journal:  Neural Regen Res       Date:  2023-01       Impact factor: 6.058

Review 8.  Alzheimer's disease: phenotypic approaches using disease models and the targeting of tau protein.

Authors:  Elisabetta Lauretti; Domenico Praticò
Journal:  Expert Opin Ther Targets       Date:  2020-03-06       Impact factor: 6.902

9.  Extending the Calpain-Cathepsin Hypothesis to the Neurovasculature: Protection of Brain Endothelial Cells and Mice from Neurotrauma.

Authors:  Rachel C Knopp; Ammar Jastaniah; Oleksii Dubrovskyi; Irina Gaisina; Leon Tai; Gregory R J Thatcher
Journal:  ACS Pharmacol Transl Sci       Date:  2021-02-02

Review 10.  Cerebral Hypoperfusion and Other Shared Brain Pathologies in Ischemic Stroke and Alzheimer's Disease.

Authors:  Shuying Dong; Shelly Maniar; Mioara D Manole; Dandan Sun
Journal:  Transl Stroke Res       Date:  2017-10-02       Impact factor: 6.800

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.